T. Rowe Price Investment Management, Inc. Syndax Pharmaceuticals Inc Transaction History
T. Rowe Price Investment Management, Inc.
- $166 Billion
- Q3 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 85,511 shares of SNDX stock, worth $1.12 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
85,511
Previous 283,827
69.87%
Holding current value
$1.12 Million
Previous $5.83 Million
71.74%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding SNDX
# of Institutions
228Shares Held
88.4MCall Options Held
1.01MPut Options Held
692K-
Black Rock Inc. New York, NY7.91MShares$103 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.84MShares$76.4 Million9.23% of portfolio
-
Wellington Management Group LLP Boston, MA4.99MShares$65.2 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$63.9 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.11MShares$53.7 Million6.25% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $740M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...